AIM ImmunoTech Inc. (AIM) shareholders
AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.15+0.00 (+0.13%)
Close on Nov 12, 2026Market cap $4.52MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
3.8%
1M of 30M shares
Institutional holders
18
4 new, 4 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
10 buys · 0 sales
Net bought $39.28K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Orca Capital AG | 1,793,999 | 9.90% | 13G (passive) | May 7, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AIM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 807,885 | 2.65% | $229.44K | +787,838 | 0.00% |
| Virtu Financial LLC | 124,269 | 0.41% | $35.00K | +73,374 | 0.00% |
| Morgan Stanley | 50,864 | 0.17% | $14.45K | +50,000 | 0.00% |
| Geode Capital Management, LLC | 46,003 | 0.15% | $13.06K | +16,085 | 0.00% |
| Goldman Sachs Group Inc | 32,444 | 0.11% | $9.21K | New | 0.00% |
| UBS Group AG | 28,931 | 0.10% | $8.22K | +28,930 | 0.00% |
| Susquehanna International Group, Llp | 21,859 | 0.07% | $6.21K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 17,519 | 0.06% | $4.98K | – | 0.00% |
| Ground Swell Capital, LLC | 12,222 | 0.04% | $3.47K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 4,668 | 0.02% | $1.33K | – | 0.00% |
| Continuum Advisory, LLC | 500 | 0.00% | $142 | New | 0.00% |
| Community Bank, N.A. | 132 | 0.00% | $36 | – | 0.00% |
| Harbour Investments, Inc. | 32 | 0.00% | $9 | – | 0.00% |
| Creative Financial Designs Inc /Adv | 30 | 0.00% | $9 | – | 0.00% |
| Osaic Holdings, Inc. | 15 | 0.00% | $3 | – | 0.00% |
| Hoey Investments, Inc | 10 | 0.00% | $3 | – | 0.00% |
| Intesa Sanpaolo Wealth Management | 1 | 0.00% | $0 | – | 0.00% |
| Farther Finance Advisors, LLC | 1 | 0.00% | $0 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 18 | 1M | 3.8% | 4 / 5 | 0 / 4 | 1M | 0M |
| Q1 2026 | 18 | 0M | 0.6% | 8 / 2 | 1 / 2 | 0M | 0M |
| Q4 2025 | 13 | 0M | 0.3% | 2 / 5 | 0 / 4 | 0M | 0M |
| Q3 2025 | 15 | 0M | 0.4% | 5 / 3 | 1 / 2 | 0M | 0M |
| Q2 2025 | 12 | 0M | 0.0% | 2 / 1 | 2 / 24 | 0M | 0M |
| Q1 2025 | 34 | 0M | 0.2% | 5 / 5 | 4 / 6 | 0M | 0M |
| Q4 2024 | 35 | 0M | 0.2% | 6 / 4 | 7 / 4 | 0M | 0M |
| Q3 2024 | 33 | 0M | 0.3% | 5 / 6 | 5 / 7 | 0M | 0M |
| Q2 2024 | 36 | 0M | 0.3% | 6 / 8 | 4 / 3 | 0M | 0M |
| Q1 2024 | 33 | 0M | 0.1% | 2 / 6 | 7 / 7 | 0M | 0M |
| Q4 2023 | 38 | 0M | 0.1% | 4 / 6 | 6 / 4 | 0M | 0M |
| Q3 2023 | 38 | 0M | 0.1% | 6 / 6 | 7 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
2 funds held AIM in Q2 2026, 0% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AIM | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 27,999 | 0.09% | $11.42K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 682 | 0.00% | $278 | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Thomas K. Equels | CEO & President, Director | 306,095 | 1.01% | Nov 12, 2026 |
| Peter W. Rodino III | COO, Secretary, Gen. Counsel | 401,762 | 1.32% | Apr 4, 2025 |
| David I. Chemerow | Director | 31,882 | 0.10% | Mar 16, 2026 |
| Ted D. Kellner | Director | 2,006,709 | 6.59% | Jul 21, 2025 |
| William M. Mitchell | Director | 522,103 | 1.72% | Apr 23, 2025 |
| Nancy Bryan | Director | 291,882 | 0.96% | Mar 18, 2025 |
| Stewart Appelrouth | Director | 388,729 | 1.28% | Jan 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Thomas K. Equels CEO & President, Director | Nov 10, 2026 | Buy | +39,000 | $0.14 | $5.38K | 293,095 |
| Thomas K. Equels CEO & President, Director | Nov 9, 2026 | Buy | +31,298 | $0.16 | $5.07K | 254,095 |
| Thomas K. Equels CEO & President, Director | Nov 6, 2026 | Buy | +12,751 | $0.16 | $2.01K | 222,797 |
| Thomas K. Equels CEO & President, Director | Nov 6, 2026 | Buy | +20,299 | $0.16 | $3.17K | 210,046 |
| Thomas K. Equels CEO & President, Director | Oct 23, 2026 | Buy | +31,675 | $0.16 | $5.07K | 189,747 |
| Thomas K. Equels CEO & President, Director | Oct 22, 2026 | Buy | +31,250 | $0.16 | $5.09K | 158,072 |
| Thomas K. Equels CEO & President, Director | Sep 17, 2026 | Buy | +24,000 | $0.21 | $5.04K | 126,822 |
| Thomas K. Equels CEO & President, Director | Sep 16, 2026 | Buy | +11,000 | $0.21 | $2.31K | 102,822 |
| Thomas K. Equels CEO & President, Director | Sep 15, 2026 | Buy | +22,000 | $0.22 | $4.84K | 91,822 |
| Thomas K. Equels CEO & President, Director | Sep 14, 2026 | Buy | +5,900 | $0.22 | $1.30K | 69,822 |
| Thomas K. Equels CEO & President, Director | Mar 12, 2026 | Conversion | +25,000 | – | – | 63,922 |
| David I. Chemerow Director | Mar 12, 2026 | Conversion | +25,000 | – | – | 28,441 |
| David I. Chemerow Director | Feb 5, 2026 | Award | +2,800 | $1.23 | $3.44K | 3,441 |
| Thomas K. Equels CEO & President, Director | Jun 13, 2025 | Buy | +107 | $7.70 | $824 | 38,885 |
| Thomas K. Equels CEO & President, Director | Jun 12, 2025 | Buy | +103 | $8.70 | $896 | 38,675 |
| Thomas K. Equels CEO & President, Director | Apr 11, 2025 | Buy | +1,968,504 | $0.03 | $59.06K | 3,867,533 |
| William M. Mitchell Director | Apr 11, 2025 | Buy | +196,851 | $0.03 | $5.91K | 521,723 |
| Ted D. Kellner Director | Apr 11, 2025 | Buy | +1,968,504 | $0.03 | $59.06K | 1,969,504 |
| Thomas K. Equels CEO & President, Director | Apr 4, 2025 | Buy | +41,000 | $0.06 | $2.46K | 1,899,029 |
| Peter W. Rodino III COO, Secretary, Gen. Counsel | Apr 4, 2025 | Buy | +500 | $0.09 | $45 | 401,762 |
| Nancy Bryan Director | Mar 14, 2025 | Award | +44,899 | $0.12 | $5.39K | 291,882 |
| David I. Chemerow Director | Mar 14, 2025 | Award | +44,899 | $0.12 | $5.39K | 64,189 |
| William M. Mitchell Director | Mar 14, 2025 | Award | +44,899 | $0.12 | $5.39K | 324,872 |
| Thomas K. Equels CEO & President, Director | Mar 5, 2025 | Buy | +50,000 | $0.13 | $6.50K | 1,858,029 |
| Thomas K. Equels CEO & President, Director | Mar 4, 2025 | Buy | +44,000 | $0.12 | $5.28K | 1,808,029 |
| Thomas K. Equels CEO & President, Director | Mar 4, 2025 | Buy | +83,334 | $0.12 | $10.00K | 1,764,029 |
| David I. Chemerow Director | Feb 28, 2025 | Award | +19,290 | $0.14 | $2.70K | 19,290 |
| William M. Mitchell Director | Feb 28, 2025 | Award | +38,580 | $0.14 | $5.40K | 279,973 |
| Nancy Bryan Director | Feb 28, 2025 | Award | +38,580 | $0.14 | $5.40K | 246,983 |
| William M. Mitchell Director | Feb 14, 2025 | Award | +43,330 | $0.12 | $5.20K | 241,393 |
| William M. Mitchell Director | Feb 14, 2025 | Award | −43,330 | $0.12 | $5.20K | 241,393 |
| Nancy Bryan Director | Feb 14, 2025 | Award | +43,330 | $0.12 | $5.20K | 208,403 |
| William M. Mitchell Director | Jan 31, 2025 | Award | +25,797 | $0.20 | $5.16K | 198,063 |
| William M. Mitchell Director | Jan 31, 2025 | Award | −25,797 | $0.20 | $5.16K | 198,063 |
| Nancy Bryan Director | Jan 31, 2025 | Award | +25,797 | $0.20 | $5.16K | 165,073 |
| William M. Mitchell Director | Jan 15, 2025 | Award | +27,412 | $0.19 | $5.21K | 172,266 |
| William M. Mitchell Director | Jan 15, 2025 | Award | −27,412 | $0.19 | $5.21K | 172,226 |
| Nancy Bryan Director | Jan 15, 2025 | Award | +27,412 | $0.19 | $5.21K | 139,276 |
| Nancy Bryan Director | Dec 31, 2024 | Award | +26,305 | $0.20 | $5.26K | 111,864 |
| William M. Mitchell Director | Dec 31, 2024 | Award | +26,305 | $0.20 | $5.26K | 144,854 |
| Stewart Appelrouth Director | Dec 31, 2024 | Award | +8,768 | $0.20 | $1.75K | 388,729 |
| William M. Mitchell Director | Dec 19, 2024 | Sale | −4,580 | $0.19 | $870 | 118,549 |
| Thomas K. Equels CEO & President, Director | Dec 18, 2024 | Buy | +22,727 | $0.21 | $4.77K | 1,680,695 |
| William M. Mitchell Director | Dec 13, 2024 | Award | +24,452 | $0.21 | $5.13K | 123,803 |
| Nancy Bryan Director | Dec 13, 2024 | Award | +24,452 | $0.21 | $5.13K | 85,559 |
| Stewart Appelrouth Director | Dec 13, 2024 | Award | +24,452 | $0.21 | $5.13K | 379,961 |
| Stewart Appelrouth Director | Dec 2, 2024 | Buy | +11,111 | $0.21 | $2.33K | 355,509 |
| Stewart Appelrouth Director | Dec 2, 2024 | Buy | +1 | $0.21 | $0 | 344,398 |
| Nancy Bryan Director | Dec 2, 2024 | Award | +22,645 | $0.23 | $5.21K | 61,107 |
| Stewart Appelrouth Director | Dec 2, 2024 | Award | +22,645 | $0.23 | $5.21K | 344,397 |
| William M. Mitchell Director | Dec 2, 2024 | Award | +22,645 | $0.23 | $5.21K | 99,351 |
| Thomas K. Equels CEO & President, Director | Nov 21, 2024 | Buy | +20,000 | $0.21 | $4.20K | 1,657,968 |
| Thomas K. Equels CEO & President, Director | Nov 20, 2024 | Buy | +85,000 | $0.20 | $17.00K | 1,637,968 |
| Stewart Appelrouth Director | Nov 20, 2024 | Buy | +81,953 | $0.19 | $15.57K | 321,752 |
| Thomas K. Equels CEO & President, Director | Nov 20, 2024 | Buy | +60,110 | $0.18 | $10.82K | 1,552,968 |
| Thomas K. Equels CEO & President, Director | Sep 16, 2024 | Buy | +5,000 | $0.30 | $1.50K | 1,493,042 |
| Thomas K. Equels CEO & President, Director | Sep 13, 2024 | Buy | +20,000 | $0.31 | $6.20K | 1,488,042 |
| Thomas K. Equels CEO & President, Director | Sep 11, 2024 | Award | +312,500 | $0.32 | $100.00K | 1,468,042 |
| Thomas K. Equels CEO & President, Director | Aug 12, 2024 | Award | +377,358 | $0.27 | $101.89K | 1,155,542 |
| Peter W. Rodino III COO, Secretary, Gen. Counsel | Aug 12, 2024 | Award | +188,679 | $0.27 | $50.94K | 401,262 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
3.78%
1M shares short
Days to cover
2.5
At 0M shares a day
Change since last report
-7.2%
From 1M shares
Short volume, 20 days
36.7%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of AIM ImmunoTech's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,712,926 shares on Sep 1, 2026 over the last 90 days.
See a number that looks wrong?